| PRODUCT | DETAILS |
|---|---|
| Zejula | — |
| Optune | — |
| Nuzyra | — |
| Bemarituzumab | — |
China-focused in-licensing and development specialist that bridges western innovation into China. Partners with GSK, Novartis, Incyte and others. Zejula (niraparib) is its lead oncology asset. Dual-listed NASDAQ (ZLAB) and HKEX (9688.HK). Strategy centers on acquiring Greater China rights to western drugs.